These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62 related articles for article (PubMed ID: 7823874)
1. [Protein kinase C. Key enzyme for immune reactions and cell growth]. Hellwiq B Med Monatsschr Pharm; 1994 Nov; 17(11):326-8. PubMed ID: 7823874 [No Abstract] [Full Text] [Related]
2. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1. Szallasi Z; Du L; Levine R; Lewin NE; Nguyen PN; Williams MD; Pettit GR; Blumberg PM Cancer Res; 1996 May; 56(9):2105-11. PubMed ID: 8616857 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of novel protein kinase C delta in BL6 murine melanoma cells inhibits the proliferative capacity in vitro but enhances the metastatic potential in vivo. La Porta CA; Di Dio A; Porro D; Comolli R Melanoma Res; 2000 Apr; 10(2):93-102. PubMed ID: 10803709 [TBL] [Abstract][Full Text] [Related]
4. Protein kinase C in signal transduction and carcinogenesis. Blumberg PM; Acs G; Areces LB; Kazanietz MG; Lewin NE; Szallasi Z Prog Clin Biol Res; 1994; 387():3-19. PubMed ID: 7972255 [No Abstract] [Full Text] [Related]
5. Bryostatin-1 enhances the maturation and antigen-presenting ability of murine and human dendritic cells. Do Y; Hegde VL; Nagarkatti PS; Nagarkatti M Cancer Res; 2004 Sep; 64(18):6756-65. PubMed ID: 15374994 [TBL] [Abstract][Full Text] [Related]
6. Protein kinase C as the receptor for the phorbol ester tumor promoters: sixth Rhoads memorial award lecture. Blumberg PM Cancer Res; 1988 Jan; 48(1):1-8. PubMed ID: 3275491 [No Abstract] [Full Text] [Related]
7. Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells. Basu A; Weixel K; Saijo N Cell Growth Differ; 1996 Nov; 7(11):1507-12. PubMed ID: 8930400 [TBL] [Abstract][Full Text] [Related]
8. Towards selective pharmacological modulation of protein kinase C--opportunities for the development of novel antineoplastic agents. Gescher A Br J Cancer; 1992 Jul; 66(1):10-9. PubMed ID: 1637658 [No Abstract] [Full Text] [Related]
9. Inhibition of phorbol ester-induced T cell proliferation by bryostatin is associated with rapid degradation of protein kinase C. Isakov N; Galron D; Mustelin T; Pettit GR; Altman A J Immunol; 1993 Feb; 150(4):1195-204. PubMed ID: 8432975 [TBL] [Abstract][Full Text] [Related]
10. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity. Berkow RL; Schlabach L; Dodson R; Benjamin WH; Pettit GR; Rustagi P; Kraft AS Cancer Res; 1993 Jun; 53(12):2810-5. PubMed ID: 8504423 [TBL] [Abstract][Full Text] [Related]
11. Bryostatin 1 affects P-glycoprotein phosphorylation but not function in multidrug-resistant human breast cancer cells. Scala S; Dickstein B; Regis J; Szallasi Z; Blumberg PM; Bates SE Clin Cancer Res; 1995 Dec; 1(12):1581-7. PubMed ID: 9815959 [TBL] [Abstract][Full Text] [Related]
12. Modulation of drug-induced apoptosis by interruption of the protein kinase C signal transduction pathway: a new therapeutic strategy. Grant S; Jarvis WD Clin Cancer Res; 1996 Dec; 2(12):1915-20. PubMed ID: 9816149 [No Abstract] [Full Text] [Related]
13. Protein kinase C--a novel target for rational anti-cancer drug design? Gescher A; Dale IL Anticancer Drug Des; 1989 Aug; 4(2):93-105. PubMed ID: 2679620 [No Abstract] [Full Text] [Related]
15. Inhibition of PMA-induced human T cell proliferation by bryostatin is associated with enhanced degradation of conventional protein kinase C (cPKC): Ca2+ signals restore mitogenic activity without abrogating enhanced cPKC degradation. Galron D; Tamir A; Altman A; Isakov N Cell Immunol; 1994 Oct; 158(1):195-207. PubMed ID: 8087865 [TBL] [Abstract][Full Text] [Related]
16. The role of growth factors in the activity of pharmacological differentiation agents. Matsui WH; Gladstone DE; Vala MS; Barber JP; Brodsky RA; Smith BD; Jones RJ Cell Growth Differ; 2002 Jun; 13(6):275-83. PubMed ID: 12114217 [TBL] [Abstract][Full Text] [Related]
17. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256 [TBL] [Abstract][Full Text] [Related]
18. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1. Mohammad RM; Varterasian ML; Almatchy VP; Hannoudi GN; Pettit GR; Al-Katib A Clin Cancer Res; 1998 May; 4(5):1337-43. PubMed ID: 9607595 [TBL] [Abstract][Full Text] [Related]
19. Posttranslational regulation of Lck and a p36-38 protein by activators of protein kinase C: differential effects of the tumor promoter, PMA, and the non-tumor-promoter, bryostatin. Galron D; Ansotegui IJ; Isakov N Cell Immunol; 1997 Jun; 178(2):141-51. PubMed ID: 9225005 [TBL] [Abstract][Full Text] [Related]
20. Modulation of protein kinase C activity and calcium-sensitive isoform expression in human myeloid leukemia cells by bryostatin 1: relationship to differentiation and ara-C-induced apoptosis. Grant S; Turner AJ; Freemerman AJ; Wang Z; Kramer L; Jarvis WD Exp Cell Res; 1996 Oct; 228(1):65-75. PubMed ID: 8892972 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]